Molar villous fluid suppresses mononuclear cell cytotoxicity

V. Fülöp, Bruce B. Feinberg, Michael A. Steller, Deborah J. Anderson, Ross S. Berkowitz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Complete molar pregnancy tissue is an allograft to the mother because all molar chromosomes are of paternal origin. Interactions between molar tissue and the maternal immune system may be important in the natural history of complete molar pregnancy. Molar villous fluid (MVF) has previously been demonstrated to suppress both mitogen and interleukin-2-induced T lymphocyte proliferation. The current study was undertaken to evaluate the potential effect of MVF on the cytotoxic activity of mononuclear cells (MNC) and lymphokine-activated mononuclear cells (LA-MNC). Sera and molar villous fluid were obtained from four women at the time of molar evacuation. K-562 erythroblastoid cells were used as target cells for MNC-mediated lysis, and JEG-3 choriocarcinoma cells were used as targets for LA-MNC-mediated lysis in a 51Cr release assay. Relative to patient sera, all MVF tested significantly inhibited both MNC and LA-MNC lysis of target cells (48.3 and 91% mean inhibition, respectively; P <0.05). This study provides additional evidence that molar gestational tissue produces factor(s) that suppress maternal immunologic responses. Potential therapies may become available to reduce or eliminate the immunosuppressive effects of molar gestations resulting in a more favorable clinical outcome in patients with complete molar pregnancy and postmolar gestational trophoblastic tumors.

Original languageEnglish
Pages (from-to)311-316
Number of pages6
JournalGynecologic Oncology
Volume47
Issue number3
DOIs
Publication statusPublished - 1992

Fingerprint

Hydatidiform Mole
Lymphokines
Mothers
Trophoblastic Neoplasms
Choriocarcinoma
Thromboplastin
Immunosuppressive Agents
Serum
Mitogens
Interleukin-2
Allografts
Immune System
Chromosomes
T-Lymphocytes
Pregnancy
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Fülöp, V., Feinberg, B. B., Steller, M. A., Anderson, D. J., & Berkowitz, R. S. (1992). Molar villous fluid suppresses mononuclear cell cytotoxicity. Gynecologic Oncology, 47(3), 311-316. https://doi.org/10.1016/0090-8258(92)90132-3

Molar villous fluid suppresses mononuclear cell cytotoxicity. / Fülöp, V.; Feinberg, Bruce B.; Steller, Michael A.; Anderson, Deborah J.; Berkowitz, Ross S.

In: Gynecologic Oncology, Vol. 47, No. 3, 1992, p. 311-316.

Research output: Contribution to journalArticle

Fülöp, V, Feinberg, BB, Steller, MA, Anderson, DJ & Berkowitz, RS 1992, 'Molar villous fluid suppresses mononuclear cell cytotoxicity', Gynecologic Oncology, vol. 47, no. 3, pp. 311-316. https://doi.org/10.1016/0090-8258(92)90132-3
Fülöp, V. ; Feinberg, Bruce B. ; Steller, Michael A. ; Anderson, Deborah J. ; Berkowitz, Ross S. / Molar villous fluid suppresses mononuclear cell cytotoxicity. In: Gynecologic Oncology. 1992 ; Vol. 47, No. 3. pp. 311-316.
@article{857aa701b0c74de0ae0608e2b2f6f488,
title = "Molar villous fluid suppresses mononuclear cell cytotoxicity",
abstract = "Complete molar pregnancy tissue is an allograft to the mother because all molar chromosomes are of paternal origin. Interactions between molar tissue and the maternal immune system may be important in the natural history of complete molar pregnancy. Molar villous fluid (MVF) has previously been demonstrated to suppress both mitogen and interleukin-2-induced T lymphocyte proliferation. The current study was undertaken to evaluate the potential effect of MVF on the cytotoxic activity of mononuclear cells (MNC) and lymphokine-activated mononuclear cells (LA-MNC). Sera and molar villous fluid were obtained from four women at the time of molar evacuation. K-562 erythroblastoid cells were used as target cells for MNC-mediated lysis, and JEG-3 choriocarcinoma cells were used as targets for LA-MNC-mediated lysis in a 51Cr release assay. Relative to patient sera, all MVF tested significantly inhibited both MNC and LA-MNC lysis of target cells (48.3 and 91{\%} mean inhibition, respectively; P <0.05). This study provides additional evidence that molar gestational tissue produces factor(s) that suppress maternal immunologic responses. Potential therapies may become available to reduce or eliminate the immunosuppressive effects of molar gestations resulting in a more favorable clinical outcome in patients with complete molar pregnancy and postmolar gestational trophoblastic tumors.",
author = "V. F{\"u}l{\"o}p and Feinberg, {Bruce B.} and Steller, {Michael A.} and Anderson, {Deborah J.} and Berkowitz, {Ross S.}",
year = "1992",
doi = "10.1016/0090-8258(92)90132-3",
language = "English",
volume = "47",
pages = "311--316",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Molar villous fluid suppresses mononuclear cell cytotoxicity

AU - Fülöp, V.

AU - Feinberg, Bruce B.

AU - Steller, Michael A.

AU - Anderson, Deborah J.

AU - Berkowitz, Ross S.

PY - 1992

Y1 - 1992

N2 - Complete molar pregnancy tissue is an allograft to the mother because all molar chromosomes are of paternal origin. Interactions between molar tissue and the maternal immune system may be important in the natural history of complete molar pregnancy. Molar villous fluid (MVF) has previously been demonstrated to suppress both mitogen and interleukin-2-induced T lymphocyte proliferation. The current study was undertaken to evaluate the potential effect of MVF on the cytotoxic activity of mononuclear cells (MNC) and lymphokine-activated mononuclear cells (LA-MNC). Sera and molar villous fluid were obtained from four women at the time of molar evacuation. K-562 erythroblastoid cells were used as target cells for MNC-mediated lysis, and JEG-3 choriocarcinoma cells were used as targets for LA-MNC-mediated lysis in a 51Cr release assay. Relative to patient sera, all MVF tested significantly inhibited both MNC and LA-MNC lysis of target cells (48.3 and 91% mean inhibition, respectively; P <0.05). This study provides additional evidence that molar gestational tissue produces factor(s) that suppress maternal immunologic responses. Potential therapies may become available to reduce or eliminate the immunosuppressive effects of molar gestations resulting in a more favorable clinical outcome in patients with complete molar pregnancy and postmolar gestational trophoblastic tumors.

AB - Complete molar pregnancy tissue is an allograft to the mother because all molar chromosomes are of paternal origin. Interactions between molar tissue and the maternal immune system may be important in the natural history of complete molar pregnancy. Molar villous fluid (MVF) has previously been demonstrated to suppress both mitogen and interleukin-2-induced T lymphocyte proliferation. The current study was undertaken to evaluate the potential effect of MVF on the cytotoxic activity of mononuclear cells (MNC) and lymphokine-activated mononuclear cells (LA-MNC). Sera and molar villous fluid were obtained from four women at the time of molar evacuation. K-562 erythroblastoid cells were used as target cells for MNC-mediated lysis, and JEG-3 choriocarcinoma cells were used as targets for LA-MNC-mediated lysis in a 51Cr release assay. Relative to patient sera, all MVF tested significantly inhibited both MNC and LA-MNC lysis of target cells (48.3 and 91% mean inhibition, respectively; P <0.05). This study provides additional evidence that molar gestational tissue produces factor(s) that suppress maternal immunologic responses. Potential therapies may become available to reduce or eliminate the immunosuppressive effects of molar gestations resulting in a more favorable clinical outcome in patients with complete molar pregnancy and postmolar gestational trophoblastic tumors.

UR - http://www.scopus.com/inward/record.url?scp=0027077832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027077832&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90132-3

DO - 10.1016/0090-8258(92)90132-3

M3 - Article

VL - 47

SP - 311

EP - 316

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -